Economists have largely ignored sex work despite it being a large industry worth almost $100bn annually, with new research methods emerging to study this complex market.

Random numbers are very important to us in this computer age, being used for all sorts of security and cryptographic tasks. [Theory to Thing] recently built a device to generate random numbers using ...

One of the best Hades-style roguelikes I've played, Lost in Random: The Eternal Die offers unique mechanics and doesn't outstay its welcome.

A new network paradigm can generate meaningfully random numbers—and fast. In network encryption, randomness has huge value because it’s not “solvable” by hackers. Classical computers can’t be ...

Researchers have developed an AI image generator that produces images in just four steps, rather than dozens.

When a worker thread completes a task, it doesn't return a sprawling transcript of every failed attempt; it returns a compressed summary of the successful tool calls and conclusions.

Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100 million for its AI-powered drug discovery operations. Incubated by Flagship Pioneering, Generate applies AI ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

Kelly-Ann Franklin has spent more than two decades in journalism which has helped her build a wide knowledge base of business and personal finance topics. Her goal with editing is to ensure tough ...

Imagine stepping into an original D&D setting that’s been lovingly written and DM’d by Tim Burton or Shel Silverstein. Instead of elves and dwarves, you have a giant card shop that’s also a person, a ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...